Details of the Drug

General Information of Drug (ID: DM2HKC4)

• Drug Name: Fluorometholone
• Synonyms: Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Fml (TN); Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Approved	[1]

• Therapeutic Class: Antiallergic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 376.5
  Topological Polar Surface Area (xlogp); 2
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 5
• Chemical Identifiers:
  Formula: C22H29FO4
  IUPAC Name: (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
  Canonical SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
  InChI: InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
  InChIKey: FAOZLTXFLGPHNG-KNAQIMQKSA-N
• Cross-matching ID:
  PubChem CID: 9878
  ChEBI ID: CHEBI:31625
  CAS Number: 426-13-1
  DrugBank ID: DB00324
  TTD ID: D0P0HT
  INTEDE ID: DR0716
  ACDINA ID: D01094

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Binder	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[3]

Molecular Expression Atlas of This Drug

• The Studied Disease: Chronic obstructive pulmonary disease
• ICD Disease Classification: CA22

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Fluorometholone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Fluorometholone caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[20]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Fluorometholone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[20]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Fluorometholone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Fluorometholone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Fluorometholone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Fluorometholone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Fluorometholone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Fluorometholone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Fluorometholone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Fluorometholone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Fluorometholone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Fluorometholone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Fluorometholone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Fluorometholone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Fluorometholone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Fluorometholone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Fluorometholone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Fluorometholone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Fluorometholone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Fluorometholone caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Fluorometholone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[20]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Fluorometholone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Fluorometholone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Fluorometholone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Fluorometholone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Fluorometholone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[20]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Benzalkonium chloride	E00536	21988052	Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
Edetate disodium	E00186	8759	Complexing agent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium dihydrogenorthophosphate	E00559	23672064	Buffering agent; Complexing agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Sodium phosphate dibasic dihydrate	E00498	6451167	Buffering agent; Complexing agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fluorometholone 0.1% suspension	0.10%	Suspension	Ophthalmic

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20.
• [3] Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
• [4] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [5] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [6] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [7] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [8] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [9] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [10] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [11] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [12] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [13] Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
• [16] Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
• [17] Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
• [18] PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
• [19] The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
• [20] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]